Potential role of body fluid ¹H NMR metabonomics as a prognostic and diagnostic tool

References

• Superko HR. Lipoprotein subclasses and atherosclerosis. Front. Biosci.6, 355–365 (2001).
   Google Scholar
• Stein JH, McBride PE. Should advanced lipoprotein testing be used in clinical practice? Nat. Clin. Pract. Cardiovasc. Med.3, 640–641 (2006).
   PubMedGoogle Scholar
• Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med.26, 847–870 (2006).
   PubMed Web of Science ®Google Scholar
• Ala-Korpela M, Lankinen N, Salminen A et al. The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. Atherosclerosis190, 352–358 (2007).
   PubMedGoogle Scholar
• McNamara JR, Warnick GR, Cooper GR. A brief history of lipid and lipoprotein measurements and their contribution to clinical chemistry. Clin. Chim. Acta369, 158–167 (2006).
   PubMedGoogle Scholar
• Griffin JL. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol.7, 648–654 (2003).
   PubMed Web of Science ®Google Scholar
• Mäkinen VP, Soininen P, Forsblom C et al. Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum. Magn. Reson. Mater. Phy.19, 281–296 (2006).
   Web of Science ®Google Scholar
• Tang H, Wang Y, Nicholson JK, Lindon JC. Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. Anal. Biochem.325, 260–272 (2004).
   PubMed Web of Science ®Google Scholar
• Ala-Korpela M, Sipola P, Kaski K. Characterization and molecular detection of atherothrombosis by magnetic resonance – potential tools for individual risk assessment and diagnostics. Ann. Med.38, 322–336 (2006).
   PubMed Web of Science ®Google Scholar
• Suna T, Salminen A, Soininen P et al. 1H NMR metabonomics of plasma lipoprotein subclasses: elucidation of metabolic clustering by self-organising maps. NMR Biomed.20, 658–672 (2007).
   PubMedGoogle Scholar
• Nicholson JK, Wilson ID. Understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug. Disc.2, 668–676 (2003).
   PubMed Web of Science ®Google Scholar
• Clayton TA, Lindon JC, Cloarec O et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature440, 1073–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Fernie AF, Trethewey RN, Krotzky AJ, Willmitzer L. Metabolite profiling: from diagnostics to systems biology. Nat. Rev. Mol. Cell Biol.5, 1–7 (2004).
   Google Scholar
• Griffin JL. The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Phil. Trans. R. Soc. B361, 147–161 (2006).
   PubMed Web of Science ®Google Scholar
• van der Greef J, Stroobant P, van der Heijden R. The role of analytical sciences in medical systems biology. Curr. Opin. Chem. Biol.8, 559–565 (2004).
   PubMed Web of Science ®Google Scholar
• Festa A, Williams K, Hanley AJG et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation111, 3465–3472 (2005).
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr. Atheroscler. Rep.6, 381–387 (2004).
   PubMedGoogle Scholar
• Kathiresan S, Otvos JD, Sullivan LM et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation113, 20–29 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai MY, Georgopoulos A, Otvos JD et al. Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. Clin. Chem.50, 1201–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Vehtari A, Mäkinen VP, Soininen P et al. A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinformatics8, S8 (2007).
   PubMedGoogle Scholar
• Smith LM, Maher AD, Cloarec O et al. Statistical correlation and projection methods for improved information recovery from diffusion-edited NMR spectra of biological samples. Anal. Chem.79, 5682–5689 (2007).
   PubMedGoogle Scholar
• Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J. Proteome Res.6, 469–479 (2007).
   PubMed Web of Science ®Google Scholar
• Beckonert O, Monnerjahn J, Bonk U, Leibfritz D. Visualizing metabolic changes in breast-cancer tissue using 1H NMR spectroscopy and self-organizing maps. NMR Biomed.16, 1–11 (2003).
   PubMedGoogle Scholar
• Cloarec O, Dumas ME, Trygg J et al. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabonomic studies. Anal. Chem.77, 517–526 (2005).
   PubMed Web of Science ®Google Scholar
• Cloarec O, Dumas ME, Craig A et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal. Chem.77, 1282–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Crockford DJ, Holmes E, Lindon JC et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem.78, 363–371 (2006).
   PubMed Web of Science ®Google Scholar
• Keun HC, Ebbels TM, Antti H et al. Analytical reproducibility in 1H NMR-based metabonomic urinalysis. Chem. Res. Toxicol.15, 1380–1386 (2002).
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Wilson ID, Morgan SR, Nash AF. A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J. Pharm. Biomed. Anal.33, 1103–1115 (2003).
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Wilson ID et al. Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal.36, 841–849 (2004).
   PubMed Web of Science ®Google Scholar
• Lauridsen M, Hansen SH, Jaroszewski JW, Cornett C. Human urine as test material in 1H NMR-based metabonomics: recommendations for sample preparation and storage. Anal. Chem.79, 1181–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh MC, Brennan L, Malthouse JP, Roche HM, Gibney MJ. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am. J. Clin. Nutr.84, 531–539 (2006).
   PubMed Web of Science ®Google Scholar
• Teahan O, Gamble S, Holmes E et al. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal. Chem.78, 4307–4318 (2006).
   PubMed Web of Science ®Google Scholar
• Brindle JT, Antti H, Holmes E et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med.8, 1439–1444 (2002).
   PubMed Web of Science ®Google Scholar
• Kirschenlohr HL, Griffin JL, Clarke SC et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat. Med.12, 705–710 (2006).
   PubMed Web of Science ®Google Scholar
• Roussel R, Mentre F, Bouchemal N et al. DIABHYCAR Study Group. NMR-based prediction of cardiovascular risk in diabetes. Nat. Med.13, 399–400 (2007).
   PubMedGoogle Scholar
• Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J. Thromb. Thrombolysis17, 35–44 (2004).
   PubMed Web of Science ®Google Scholar
• Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat. Rev. Drug. Disc.3, 913–925 (2004).
   PubMed Web of Science ®Google Scholar
• Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ; Pittsburgh Epidemiology of Diabetes Complications Study. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia46, 674–682 (2003).
   PubMed Web of Science ®Google Scholar
• Klein RL, McHenry MB, Lok KH et al.; DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with lipoprotein subclasses. Metabolism53, 1296–1304 (2004).
   PubMedGoogle Scholar
• Garvey WT, Kwon S, Zheng D et al. Effects of insulin resistance and Type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes52, 453–462 (2003).
   PubMed Web of Science ®Google Scholar
• Salek RM, Maguire ML, Bentley E et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol. Genomics.29, 99–108 (2007).
   PubMed Web of Science ®Google Scholar
• Odunsi K, Wollman RM, Ambrosone CB et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int. J. Cancer113, 782–788 (2005).
   PubMed Web of Science ®Google Scholar
• Griffin JL, Kauppinen RA. A metabolomics perspective of human brain tumours. FEBS J.274, 1132–1139 (2007).
   PubMed Web of Science ®Google Scholar
• Moolenaar SH, Engelke UF, Wevers RA. Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism. Ann. Clin. Biochem.40, 16–24 (2003).
   PubMedGoogle Scholar
• Duarte IF, Goodfellow BJ, Barros A et al. Metabolic characterisation of plasma in juveniles with glycogen storage disease type 1a (GSD1a) by high-resolution 1H NMR spectroscopy. NMR Biomed.20, 401–412 (2007).
   PubMedGoogle Scholar
• Hewer R, Vorster J, Steffens FE, Meyer D. Applying biofluid 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on antiretroviral treatment and HIV-1 negative individuals. J. Pharm. Biomed. Anal.41, 1442–1446 (2006).
   PubMedGoogle Scholar
• Tsang TM, Huang JT, Holmes E, Bahn S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J. Proteome Res.5, 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Holmes E, Tsang TM, Huang JT et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med.3, E327 (2006).
   PubMedGoogle Scholar
• Holmes E, Tsang TM, Tabrizi SJ. The application of NMR-based metabonomics in neurological disorders. NeuroRx3, 358–372 (2006).
   PubMedGoogle Scholar
• Wang Y, Holmes E, Tang H et al. Experimental metabonomic model of dietary variation and stress interactions. J. Proteome Res.5, 1535–1542 (2006).
   PubMed Web of Science ®Google Scholar
• Wishart DS. Metabolomics: the principles and potential applications to transplantation. Am. J. Transplant.5, 2814–2820 (2005).
   PubMed Web of Science ®Google Scholar
• Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU. 1H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int.67, 1142–1151 (2005).
   PubMed Web of Science ®Google Scholar
• Serkova NJ, Zhang Y, Coatney JL et al. Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation83, 517–521 (2007).
   PubMed Web of Science ®Google Scholar
• Pearson H. Meet the human metabolome. Nature446, 8 (2007).
   PubMedGoogle Scholar
• Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug. Discov.1, 153–161 (2002).
   PubMed Web of Science ®Google Scholar
• Waters NJ, Waterfield CJ, Farrant RD, Holmes E, Nicholson JK. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem. Res. Toxicol.18, 639–654 (2005).
   PubMed Web of Science ®Google Scholar
• Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics6, 691–699 (2005).
   PubMed Web of Science ®Google Scholar
• Viant MR, Lyeth BG, Miller MG, Berman RF. An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model. NMR Biomed.18, 507–516 (2005).
   PubMed Web of Science ®Google Scholar
• Tsang TM, Woodman B, McLoughlin GA et al. Metabolic characterization of the R6/2 transgenic mouse model of Huntington’s disease by high-resolution MAS 1H NMR spectroscopy. J. Proteome Res.5, 483–492 (2006).
   PubMed Web of Science ®Google Scholar
• Coen M, Ruepp SU, Lindon JC et al. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J. Pharm. Biomed. Anal.35, 93–105 (2004).
   PubMed Web of Science ®Google Scholar
• Craig A, Sidaway J, Holmes E et al. Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res.5, 1586–1601 (2006).
   PubMed Web of Science ®Google Scholar
• Selman C, Kerrison ND, Cooray A et al. Coordinated multitissue transcriptional and plasma metabonomic profiles following acute caloric restriction in mice. Physiol. Genomics.27, 187–200 (2006).
   PubMed Web of Science ®Google Scholar
• Dumas ME, Wilder SP, Bihoreau MT et al. Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models. Nat. Genet.39, 666–672 (2007).
   PubMed Web of Science ®Google Scholar
• Mayr M, Madhu B, Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc. Med.17, 43–48 (2007).
   PubMedGoogle Scholar
• Martin FP, Dumas ME, Wang Y et al. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol.3, 112 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson I. Top-down versus bottom-up – rediscovering physiology via systems biology? Mol. Syst. Biol.3, 113 (2007).
   PubMedGoogle Scholar
• Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol.2, 52 (2006).
   PubMed Web of Science ®Google Scholar
• Fuster V, Voûte J. Expanding the cardiovascular mandate: from treatment to the protection of health. Nat. Clin. Pract. Cardiovasc. Med.4, 117 (2007).
   PubMedGoogle Scholar